U.S., July 9 -- ClinicalTrials.gov registry received information related to the study (NCT07053007) titled 'Phase I Umbilical CB-NK Expressing sIL-15 & PD-L1 +/- Atezolizumab in NSCLC Pts Refractory to PD-1/PD-L1' on June 30.
Brief Summary: This is a Phase 1 dose escalation clinical trial determining the maximum tolerated dose of NK-102 in subjects with advanced, metastatic, or recurrent non-small cell lung cancer (NSCLC) (previously treated with PD1 and/or PD-L1 immune checkpoint inhibitors) as monotherapy or in combination with atezolizumab.
Study Start Date: Sept., 2025
Study Type: INTERVENTIONAL
Condition:
Non-small Cell Lung Cancer
NSCLC
Lung Cancer, Non-small Cell
Lung Cancer
Intervention:
DRUG: NK-102
Given IV
DRUG: Atezoliz...